Aurora kinases: New molecular targets in thyroid cancer therapy

Clinica Terapeutica

Volumn 163, Issue 6, 2012, Pages

  Baldini, E ^a   Sorrenti, S ^b   D'Armiento, E ^a   Prinzi, N ^a   Guaitoli, E ^b   Favoriti, P ^b   Gnessi, L ^a   Moretti, C ^c   Bianchini, M ^a   Alessandrini, S ^a   Catania, A ^b   De Antoni, E ^b   Ulisse, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Aneuploidy; Aurora kinases; Cell cycle; Mitosis; Therapy; Thyroid cancer

Indexed keywords

PROTEIN SERINE THREONINE KINASE;

ANEUPLOIDY; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL GROWTH; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; MITOSIS; PROTEIN FUNCTION; THYROID CANCER;

AURORA KINASES; HUMANS; THYROID NEOPLASMS;

EID: 84878181257     PISSN: 00099074     EISSN: 19726007     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4:842-54
2. Zhang X, Ems-McClung SC, Walczak CE. Aurora A phosphorylates MCAK to control ran-dependent spindle bipolarity. Mol Biol Cell 2008; 19:2752-65
3. Nikonova AS, Astsaturov I, Serebriiskii IG, et al. Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci 2012 (in press)
4. Ulisse S, Baldini E, Toller M, et al. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr Relat Cancer 2007; 14:827-37
5. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007; 8:798-812
6. Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 2006; 173:833-7
7. Gabillard JC, Ulisse S, Baldini E, et al. Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 1 protein. Biochem Biophys Res Commun 2011; 408:647-53
8. Delaval B, Ferrand A, Conte N, et al. Aurora B -TACC1 protein complex in cytokinesis. Oncogene 2004; 23:4516-22
9. Slattery SD, Mancini MA, Brinkley BR, et al. Aurora-C kinase supports mitotic progression in the absence of Aurora-B. Cell Cycle 2009; 8:2984-94
10. Schindler K, Davydenko O, Fram B, et al. Maternally recruited Aurora C kinase is more stable than Aurora B to support mouse oocyte maturation and early development. Proc Natl Acad Sci U S A 2012; 109:E2215-22
11. Spengler D. The protein kinase Aurora C phosphorylates TRF2. Cell Cycle 2007; 6:2579-80
12. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008; 1786:60-72
13. Dar AA, Goff LW, Majid S, et al. Aurora kinase inhibitors--rising stars in cancer therapeutics? Mol Cancer Ther 2010; 9:268-78
14. van der Waal MS, Hengeveld RC, van der Horst A, et al. Cell division control by the Chromosomal Passenger Complex. Exp Cell Res 2012; 318:1407-20
15. Nguyen HG, Chinnappan D, Urano T, et al. Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property. Mol Cell Biol 2005; 25:4977-92
16. Wurzenberger C, Gerlich DW. Phosphatases: providing safe passage through mitotic exit. Nat Rev Mol Cell Biol 2011; 12:469-82
17. Arlot-Bonnemains Y, Klotzbucher A, Giet R, et al. Identification of a functional destruction box in the Xenopus laevis aurora-A kinase pEg2. FEBS Lett 2001; 508:149-52
18. Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet 2012; 13:189-203
19. Lok W, Klein RQ, Saif MW. Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs 2010; 21:339-50
20. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3:51-62
21. Liang X, Wang D, Wang Y, et al. Expression of Aurora Kinase A and B in chondrosarcoma and its relationship with the prognosis. Diagn Pathol 2012; 7:84
22. Liu ZG, Yi W, Tao YL, et al. Aurora-A is an efficient marker for predicting poor prognosis in human nasopharyngeal carcinoma with aggressive local invasion: 208 cases with a 10-year follow-up from a single institution. Oncol Lett 2012; 3:1237-44
23. Ali HR, Dawson SJ, Blows FM, et al. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br J Cancer 2012; 106:1798-806
24. Lehman NL, O'Donnell JP, Whiteley LJ, et al. Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle 2012; 11:489-502
25. Dotan E, Meropol NJ, Zhu F, et al. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. Br J Cancer 2012; 106:748-55
26. Wang J, Yang S, Zhang H, et al. Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep 2011; 26:23-32
27. Yang F, Guo X, Yang G, et al. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Mod Pathol 2011;24:836-45
28. Lukasiewicz KB, Lingle WL. Aurora A, centrosome structure, and the centrosome cycle. Environ Mol Mutagen 2009; 50:602-19
29. Ota T, Suto S, Katayama H, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002; 62:5168-77
30. Nguyen HG, Makitalo M, Yang D, et al. Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J 2009; 23:2741-8
31. Pannone G, Hindi SA, Santoro A, et al. Aurora B expression as a prognostic indicator and possible therapeutic target in oral squamous cell carcinoma. Int J Immunopathol Pharmacol 2011; 24:79-88
32. Lin ZZ, Jeng YM, Hu FC, et al. Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer 2010; 10:461
33. Kimura M, Matsuda Y, Yoshioka T, et al. Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 1999; 274:7334-40
34. Ulisse S, Delcros JG, Baldini E, et al. Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer 2006; 119:275-82
35. Baldini E, Arlot-Bonnemains Y, Mottolese M, et al. Deregulation of Aurora kinase gene expression in human testicular germ cell tumours. Andrologia 2010; 42:260-7
36. Khan J, Ezan F, Crémet JY, et al. Overexpression of active Aurora-C kinase results in cell transformation and tumour formation. PLoS One 2011; 6:e26512
37. Manchado E, Guillamot M, Malumbres M. Killing cells by targeting mitosis. Cell Death Differ 2012; 19:369-77
38. Cheung CH, Coumar MS, Chang JY, et al. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat 2011; 21:857-84
39. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11
40. Kinder BK. Well differentiated thyroid cancer. Curr Opin Oncol 2003; 5:71-7
41. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. Ca Cancer J Clin 2009; 59:225-49
42. Nikiforv YE, Biddinger PW, Thompson LDR (Eds) Diagnostic pathology and molecular genetics of the thyroid. Philadelphia: Lippincott Williams & Wilkins 2009
43. Trimboli P, Ulisse S, Graziano FM, et al. Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid 2006; 16:1151-5
44. Roman SA. Endocrine tumors: evaluation of thyroid nodule. Curr Opin Oncol 2003; 15:66-70
45. Welker MJ, Orlow D. Thyroid nodules. Am Fam Phys 2003; 67:559-66
46. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-214
47. Sorrenti S, Trimboli P, Catania A, et al. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm. Thyroid 2009; 19:355-60
48. Trimboli P, Ulisse S, D'Alò M, et al. Analysis of clinical, ultrasound and colour flow-Doppler characteristics in predicting malignancy in follicular thyroid neoplasms. Clin Endocrinol 2008; 69:342-4
49. Trimboli P, Condorelli E, Catania A, et al. Clinical and ultrasound parameters in the approach to thyroid nodules cytologically classified as indeterminate neoplasm. Diagn Cytopathol 2009; 37:783-5
50. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-62
51. Handkiewicz-Junak D, Czarniecka A, Jarza{ogonek}b B. Molecular prognostic markers in papillary thyroid cancer: current status and future directions. Mol Cell Endocrinol 2010; 322:8-28
52. Ulisse S, Baldini E, Sorrenti S, et al. High expression of the urokinase plasminogen activator and its cognate 1 receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metab 2011; 96:504-8
53. Ulisse S, Baldini E, Sorrenti S, et al. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin Endocrinol 2012 (in press)
54. Walsh S, Prichard R, Hill AD. Emerging therapies for thyroid carcinoma. Surgeon 2012;10:53-8
55. Schlumberger M, Carlomagno F, Baudin E, et al. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract 2008; 4:22-32
56. Antonelli A, Fallahi P, Ulisse S, et al. New targeted therapies for anaplastic thyroid cancer. Anti-Cancer Agent Med 2012; 12:87-93
57. Sorrentino R, Libertini S, Pallante PL, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 2005; 90:928-35
58. Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 2007; 14:719-29
59. Arlot-Bonnemains Y, Baldini E, Martin B, et al. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancerderived cell lines. Endocr Relat Cancer 2008; 15:559-68
60. Baldini E, Sorrenti S, D'Armiento E, et al. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines. Clin Ter 2012; 5:e307-13 e-pub
61. Baldini E, Arlot-Bonnemains Y, Sorrenti S, et al. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT. BMC Cancer 2011; 11:411
62. Wunderlich A, Roth S, Ramaswamy A, et al.Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer. Endocrine 2012 (in press)